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Introduction: Morning stiffness is assessed daily in the diagnostic process of arthralgia and arthritis, but large-scale
studies on the discriminative ability are absent. This study explored the diagnostic value of morning stiffness in
5,202 arthralgia and arthritis patients and the prognostic value in early rheumatoid arthritis (RA).
Methods: In arthralgia patients referred to the Early Arthritis Recognition Clinics (EARC) of Leiden (n = 807) and
Groningen (n = 481) or included in the Rotterdam Early Arthritis Cohort (REACH) study (n = 353), the associations
(cross-sectional analyses) between morning stiffness and presence of arthritis at physical examination were studied.
In early arthritis patients, included in the Leiden Early Arthritis Clinic (EAC) (n = 2,748) and Evaluation et Suivi de
POlyarthrites Indifférenciées Récentes (ESPOIR) (n = 813), associations with fulfilling the 2010-RA criteria after one
year were assessed. In 2010-RA patients included in the EAC (n = 1,140) and ESPOIR (n = 677), association with the
long-term outcomes of disease-modifying antirheumatic drug (DMARD)-free sustained remission and radiological
progression were determined. Morning stiffness was defined as a duration ≥60 minutes; sensitivity analyses were
performed for other definitions.
Results: In arthralgia, morning stiffness (≥60 minutes) associated with the presence of arthritis; Leiden EARC
odds ratio (OR) 1.49 (95% CI 1.001 to 2.20), Groningen EARC OR 2.21 (1.33 to 3.69) and REACH OR 1.55 (0.97 to 2.47)
but the areas under the receiver operating characteristic curve (AUCs) were low (0.52, 0.57, 0.54). In early arthritis,
morning stiffness was associated with 2010-RA independent of other predictors (Leiden EAC OR 1.72 (95% CI
1.31 to 2.25, AUC 0.68), ESPOIR OR 1.68 (1.03 to 2.74, AUC 0.64)). Duration of ≥30 minutes provided optimal
discrimination for RA in early arthritis. Morning stiffness was not associated with radiological progression or
DMARD-free sustained remission.
Conclusions: Morning stiffness in arthralgia and early arthritis is associated with arthritis and RA respectively. This
supports the incorporation of morning stiffness in the diagnostic process.* Correspondence: j.a.b.van_nies@lumc.nl
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Morning stiffness is common in patients with rheuma-
toid arthritis (RA); it affects the ability to function in the
morning [1], the quality of life and is associated with work
loss [2]. Presence of morning stiffness, together with fa-
tigue, are often mentioned as one of the first symptoms of
RA. Therefore, morning stiffness is usually assessed in the
diagnostic process of patients presenting with arthralgia
or arthritis [3].
The scientific data on the diagnostic value of this
symptom are surprisingly scanty. In the literature, it has
been mentioned that morning stiffness is a poor discrim-
inator between RA and other rheumatologic disorders
[4,5]. However, these conclusions are predominantly based
on two studies, with relatively small sample sizes. The first
study compared 93 RA patients and 46 patients with
non-inflammatory joint diseases [4]. The second study
compared 31 RA patients with 23 systemic lupus erythe-
matosus (SLE) patients and 34 osteoarthritis (OA) patients
[5]. It has also been suggested that morning stiffness is
commonly present in the general population and not spe-
cific for RA [6,7]. This notion is also based on only two
studies. A large study revealed a prevalence of morning
stiffness of 37% when defined as stiffness of ≥15 minutes;
this definition is generally not considered as typical for
RA [6]. The other study originated from the early 1950s
and reported morning stiffness in 19% of persons without
RA, but a definition of morning stiffness was not provided
[7]. Altogether, there is not much evidence on the diag-
nostic value of morning stiffness. It is also not part of the
2010 American College of Rheumatology (ACR)/European
League Against Rheumatism (EULAR) classification cri-
teria for RA, whereas it had been included in the 1958
American Rheumatism Association (ARA) criteria and the
1987 ACR criteria for RA [8-10]. Because of the paradox
of the lack of large-scale studies focusing on morning stiff-
ness, and the use of morning stiffness in daily practice by
rheumatologists and general practitioners, we set out to
study the diagnostic value of morning stiffness in arthral-
gia and early arthritis by studying different European data-
sets and cohorts. The basic aim to this study was to
evaluate the diagnostic value of morning stiffness. Because
the diagnostic value is dependent on the patient popula-
tion in which a test is performed, we studied the discrim-
inative ability of morning stiffness in two situations. First,
in cross-sectional analyses on patients with arthralgia, the
association between morning stiffness and the presence of
arthritis at physical examination was studied. This infor-
mation is relevant for general practitioners (GPs) and
other physicians who encounter patients with joint symp-
toms in their practices and who have limited experience
in joint examination. Second, in early arthritis, the ability
of morning stiffness to discriminate patients with RA from
other early arthritis patients was assessed.Although it is known that morning stiffness is associ-
ated with the disease activity [11], functional disability
[12] and work loss [2] in RA, it is undetermined whether
morning stiffness at first presentation is a risk factor for
a more severe disease reflected by structural damage or
disease persistence. To evaluate this, associations with
radiographic progression and achieving DMARD-free sus-
tained remission (the absence of disease persistence) were
assessed in two longitudinal cohort studies.
Methods
Patients
All datasets and cohorts used are described in more de-
tail elsewhere [13-16].
In short, the arthralgia patients were referred to
the Early Arthritis Recognition Clinics (EARC) from
Leiden and Groningen (the Netherlands) or included in
the Rotterdam Early Arthritis Cohort (REACH) (the
Netherlands). The EARCs were initiated to reduce re-
ferral delay by GPs. It was observed that the GP delay
contributed to two-thirds of the total delay between
symptom onset and first visit to a rheumatologist in the
Netherlands and that GPs frequently applied a ‘wait-
and-see’ approach if they were unsure of the presence
of arthritis. Therefore, GPs were instructed to refer to
the EARC if they were undecided. The EARCs are early
access clinics in which experienced rheumatologists screen
patients on the presence of arthritis by physical examin-
ation; no laboratory investigations are done [13,17]. The
studied arthralgia patients visited the Leiden EARC
between September 2010 and August 2013 and the
Groningen EARC between October 2010 and January
2014. The EARC is primarily part of our care. Patients
visiting the EARCs were not subjected to procedures
that were done for scientific purposes, such as blood
taking for biobanking. Therefore, in line with the Dutch
law ‘Wet medisch-wetenschappelijk onderzoek met men-
sen’ (translated as ‘the law on medical and scientific re-
search involving people’), patients were not asked to
sign an informed consent form.
The REACH study is an inception cohort that was initi-
ated in the Rotterdam area, the Netherlands, in 2004. In-
clusion required either pain or loss of movement in ≥2
joints or >1 swollen joint and ≥2 of the following items:
unable to clench a fist in the morning, pain when shaking
someone’s hand, pins and needles in the fingers, difficul-
ties wearing rings or shoes, a family history of RA, morn-
ing stiffness >1 hour, unexplained fatigue, all <1 year [14].
The patients studied here were referred with joint
symptoms by GPs between 2004 and 2009 and the pres-
ence of arthritis was assessed at the first visit. REACH
was approved by the ethics committees of all three par-
ticipating hospitals (Erasmus MC University Medical
Center Rotterdam, Sint Franciscus Gasthuis Rotterdam
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written informed consent.
The early arthritis patients were included in the Leiden
Early Arthritis Clinic (EAC) and the Evaluation et Suivi
de POlyarthrites Indifférenciées Récentes (ESPOIR) co-
hort. The Leiden EAC is a population-based inception
cohort that started in 1993. Inclusion required the pres-
ence of arthritis of ≥1 joint at physical examination and
symptom duration <2 years [15]. The patients studied
were included between 1993 and 2011. The EAC was
approved by the local Leiden University Medical Center
(LUMC) ethics committee, all patients gave informed con-
sent. ESPOIR is a nationwide cohort in which 14 rheu-
matology centres throughout France collaborate. Early
arthritis patients are included if the treating rheumatolo-
gists suspected them of having or developing RA. Further,
for inclusion patients had to be aged 18 to 70 years and to
have ≥2 swollen joints for >6 weeks and <6 months.
Patients studied were included between 2002 and 2005
[16]. ESPOIR was approved by the ethics committee of
Montpellier; all patients gave written informed consent. In
both the EAC and ESPOIR questionnaires were filled in,
joint counts performed and laboratory evaluations done at
baseline. Patients were followed prospectively with yearly
follow-up visits; these included clinical and laboratory
evaluations and radiographs of hands and feet.
Assessment of morning stiffness
In all cohorts the duration of morning stiffness was re-
ported in minutes. In the EARCs, patients answered
questionnaires on the presence and duration of morning
stiffness (Additional file 1). In the EAC, ESPOIR and
REACH the questions on presence and duration of
morning stiffness were asked by trained research nurses
(Additional file 1). Patients were not asked for specific loca-
tions of stiffness. Morning stiffness duration was dichoto-
mized into <60 and ≥60 minutes. Sensitivity analyses were
performed with ≥30 and ≥90 minutes as cutoffs. To evalu-
ate the consistency in results when morning stiffness was
assessed differently, analyses on arthritis patients were re-
peated with the severity of morning stiffness instead of the
duration. The severity was assessed using a visual analogue
scale (VAS) in 1,959 EAC patients included between 1993
and February 2010 and in all ESPOIR patients. For analyses,
the VAS was divided into the three categories; mild 0 to 33
millimeter (mm), moderate 34 to 67 mm and severe 68 to
100 mm. In the arthralgia datasets the severity was not re-
corded. In all patients studied, morning stiffness was
assessed at the first visit, when patients were not treated
with disease-modifying antirheumatic drugs (DMARDs).
Outcomes
The outcomes were different in the three parts of this
study (Figure 1).Diagnostic value in arthralgia
In arthralgia patients, the outcome was the presence of
arthritis ascertained at physical examination by experi-
enced rheumatologists (assessed at the same visit when
morning stiffness was evaluated). In both EARCs, a
small proportion of patients (58 and 25) had no evident
arthritis but were also not classified as having ‘no arth-
ritis’ because the rheumatologists suspected these pa-
tients of RA development; these patients were excluded
from analyses.
Diagnostic value in early arthritis
In early arthritis, we aimed to assess the diagnostic value
of morning stiffness and here the outcome was the pres-
ence of RA after one year. RA was defined as fulfilling
the 2010 ACR/EULAR criteria for RA during the first
year. An advantage of the 2010-RA criteria is that morn-
ing stiffness is not included, preventing circle reasoning.
Since during the first weeks the diagnoses may not yet be
definitive, the classification after year one was evaluated.
These first two parts evaluated the diagnostic value.
Prognostic value within RA
Third, within 2010-RA patients, the prognostic value was
assessed by studying two long-term outcomes. Structural
damage was assessed using serial hands and feet radio-
graphs that were scored according to the Sharp/van der
Heijde (SHS) method with known time order and blinded
to clinical data. In the EAC, radiographs were scored of
patients included between 1993 and 2006. The follow-up
was seven years in the EAC and three years in ESPOIR.
The within-reader intraclass correlation coefficients (ICCs)
were 0.91 and 0.87 for two readers in the EAC and 0.97 in
ESPOIR. DMARD-free sustained remission, the opposite
of disease persistence, was defined as the sustained ab-
sence of arthritis after discontinuation of DMARD ther-
apy, including biologics and glucocorticoids (systemic
and intra-articular), for the entire period of follow-up,
which was at least one year [18]. In the EAC, it was
assessed by exploring the medical files until 10 years of
follow-up. In ESPOIR, it was assessed over five years of
follow-up by reviewing the structured visits in the
ESPOIR database.
Analyses
Characteristics were compared using Student t tests,
Mann–Whitney tests or chi-square tests when appropri-
ate. Associations of morning stiffness in arthralgia and
early arthritis were done using logistic regression ana-
lyses. All analyses were adjusted for age and gender (al-
though morning stiffness was not correlated with age in
arthralgia or early arthritis). In early arthritis further
adjustments were made for anti-citrullinated protein anti-
body (ACPA), rheumatoid factor (RF), swollen joint count
Figure 1 Outline of study questions. Of the 2010-RA patients in the EAC, radiographs were scored for the patients included between 1993 and
2006 (n = 636). Baseline characteristics of RA patients included before or after 2006 were not different. In ESPOIR, radiographic data was available
for 659 of 677 RA patients. Here also, baseline characteristics of patients with and without radiographs were not different. EAC, Early Arthritis
Clinic; ESPOIR, Evaluation et Suivi de POlyarthrites Indifférenciées Récentes; RA, rheumatoid arthritis.
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duration at baseline. The test characteristics (sensitivity,
specificity), positive/negative predictive values (PPV/NPV)
and area under the receiver operating characteristic curve
(AUC) were calculated. This curve was used to derive the
morning stiffness duration with the optimal discriminative
ability (Youden’s index). Associations between morning
stiffness at baseline and radiographic progression were
studied using multivariate normal regression analysis with
log-transformed radiographic data as response variable as
described elsewhere [19,20]. Analyses on DMARD-free
sustained remission were done by Kaplan-Meier survival
curves and Cox proportional hazard regression models
with morning stiffness as an independent variable. Ana-
lyses on radiographic progression and DMARD-free sus-
tained remission were adjusted for age, gender, ACPA and
inclusion period as a proxy for differences in treatment
strategy as described elsewhere [17]. SPSS version 20.0
was used (IBM Corp, Armonk, NY, USA).
Results
Diagnostic value of morning stiffness in arthralgia
In the Leiden EARC, 807 arthralgia patients were seen, in
the Groningen EARC, 481 arthralgia patients and in the
REACH, 353 patients were included. Arthritis was ob-
served in 372 (46%), 267 (56%) and 181 (51%) patients re-
spectively. Table 1 presents baseline characteristics. The
median (interquartile range (IQR)) duration of morning
stiffness was 10 (0 to 30), 10 (0 to 30) and 30 (0 to 60) mi-
nutes respectively. The odds ratios (ORs) of morning stiff-
ness (≥60 minutes) for the presence on arthritis were 1.49
(95% confidence interval (CI) 1.001 to 2.20), 2.21 (1.33 to3.69) and 1.55 (0.97 to 2.47) for the Leiden EARC,
Groningen EARC and REACH respectively. The specific-
ities ranged between 73 to 85% but the sensitivities were
low (21 to 38%). The low sensitivity indicated that the ma-
jority of all patients with arthritis did not have morning
stiffness for ≥60 minutes. The PPVs were 54%, 69% and
60% respectively (Table 2) and all higher than the absolute
chances on arthritis without assessing morning stiffness
(these were 46%, 56%, 51%). The AUCs were very low
(Leiden EARC 0.52, Groningen EARC 0.57, REACH 0.54);
therefore, no duration with optimal discriminative ability
was ascertained. When morning stiffness was defined as
≥90 minutes (present in 10 to 21% of arthralgia patients),
the specificity increased to 85 to 93% (Table 2). This indi-
cated that almost all arthralgia patients without arthritis
did not have morning stiffness for ≥90 minutes.
Diagnostic value of morning stiffness in early arthritis
A total of 2,748 early arthritis patients were included in
the EAC and 813 in ESPOIR. The median duration of
morning stiffness at baseline was 30 (0 to 90) and 60 (15
to 120) minutes. Other baseline characteristics are pre-
sented in Table S1 in Additional file 1. In total, 42% and
83% of the patients were classified as 2010-RA after year
one respectively. Figure 2 shows the duration of morning
stiffness per diagnosis of early arthritis patients included
in the EAC; the median duration in RA was 60 minutes
and longer than that of other early arthritis patients (ex-
cept for SLE patients). Since ESPOIR included early
arthritis patients with a clinical suspicion of RA and not
patients with other diagnoses, this figure was not de-
rived for ESPOIR. Morning stiffness (≥60 minutes) was
Table 1 Baseline characteristics of the arthralgia patients
Leiden EARC Groningen EARC REACH
All n = 807 No arthritis
n = 435
Arthritis
n = 372
All n = 481 No arthritis
n = 214
Arthritis
n = 267
All n = 353 No arthritis
n = 172
Arthritis
n = 181
Age, mean ± SD, years 51.4 ± 16.3 49.6 ± 15.5 53.5 ± 17.0 51.6 ± 16.4 49.0 ± 15.3 53.7 ± 16.9 48.6 ± 14.1 46.7 ± 11.7 50.3 ± 15.9
Female, n (%) 574 (71) 345 (79) 229 (62) 311 (65) 145 (68) 166 (62) 277 (79) 149 (87) 128 (71)
Gradual onset symptoms, n (%) 499 (62) 285 (67) 214 (59) 299 (63) 140 (66) 159 (61) 183 (58) 115 (71) 68 (44)
Morning stiffness, minutes 10 (0–30) 10 (0–30) 10 (0–30) 10 (0–30) 10 (0–30) 15 (0–60) 30 (0–60) 30 (0–60) 30 (0–97)
≥30 minutes, n (%) 210 (30) 106 (28) 104 (32) 146 (36) 55 (30) 91 (40) 185 (53) 87 (52) 98 (54)
≥60 minutes, n (%) 129 (18) 60 (16) 69 (21) 88 (22) 27 (15) 61 (27) 114 (32) 45 (27) 68 (38)
≥90 minutes, n (%) 71 (10) 27 (7) 44 (14) 53 (13) 15 (8) 38 (17) 73 (21) 25 (15) 48 (27)
Tender joint count 7 (2–14) 8 (3–17) 5 (2–13) 9 (4–18) 9 (4–18) 8 (3–18) 7 (3–12) 7 (2–12) 7 (3–11)
Symptom duration, weeks 11.5 (4.0-61.0) 19.3 (6.1-122) 6.9 (2.7-21.6) 18.0 (5.6-64.3) 22.9 (6.9-74.9) 16.6 (4.6-54.9) 1.7 (0.8-3.2) 2.4 (1.2-3.6) 1.3 (0.7-2.3)
<12 weeks symptom duration, n (%) 380 (51) 162 (41) 218 (62) 165 (39) 70 (38) 95 (39) 352 (100) 171 (100) 181 (100)
Values are median (interquartile range) unless indicated otherwise. Missingness per variable as follows: gradual onset symptoms (defined as start of onset >1 week) Leiden EARC n = 17, Groningen EARC n = 8, REACH
n = 36); morning stiffness Leiden EARC n = 101, Groningen EARC n = 72, REACH n = 5; tender joint count Groningen EARC n = 1; symptom duration/ <12 weeks symptom duration Leiden EARC n = 61, Groningen EARC
n = 54, REACH n = 1. Patients with missing data on morning stiffness duration did not differ significantly from patients with data on morning stiffness (data not shown). EARC, Early Arthritis Recognition Clinic; REACH,
Rotterdam Early Arthritis Cohort; SD, standard deviation.
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Table 2 The diagnostic value of morning stiffness (different durations) in arthralgia for the presence of arthritis
OR (95% CI) adjusted for
age and gender
Sensitivity Specificity PPV NPV
Leiden EARC
≥30 minutes 1.24 (0.89-1.73) 31.9% 72.1% 49.5% 55.2%
≥60 minutes 1.49 (1.001-2.20) 21.2% 84.2% 53.5% 55.5%
≥90 minutes 1.98 (1.18-3.30) 13.5% 92.9% 62.0% 55.6%
Groningen EARC
≥30 minutes 1.63 (1.07-2.47) 40.3% 70.0% 62.3% 48.7%
≥60 minutes 2.21 (1.33-3.69) 27.0% 85.3% 69.3% 48.6%
≥90 minutes 2.16 (1.14-4.10) 16.8% 91.8% 71.7% 47.2%
REACH
≥30 minutes 1.07 (0.69-1.65) 54.4% 48.2% 53.0% 50.3%
≥60 minutes 1.55 (0.97-2.47) 37.8% 72.6% 59.7% 47.9%
≥90 minutes 2.05 (1.18-3.58) 26.7% 85.1% 65.8% 48.0%
OR, odds ratio; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; EARC, Early Arthritis Recognition Clinic; REACH, Rotterdam
Early Arthritis Cohort.
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CI 2.47 to 3.44) and ESPOIR (OR 2.33, 95% CI 1.59 to
3.44), also after additional adjustments for ACPA, RF, SJC,
symptom duration and ESR (OR 1.72. 95% CI 1.31 to 2.25
in EAC and OR 1.68, 95% CI 1.03 to 2.74 in ESPOIR). In
both cohorts the sensitivity and specificity were around
60%. The PPV was 56.7% in EAC and 88.7% in ESPOIR,
these absolute chances were a little higher than the
pre-test chances on RA (42% and 83%). When morningFigure 2 The duration of morning stiffness per diagnosis in the Leiden EA
of patients per diagnosis after one year of follow-up: 2010-RA n = 1,140, SL
inflammatory arthritis n = 133, reactive arthritis n = 108, SpA/PsA with perip
n = 1 and SpA/PsA with peripheral arthritis n = 1) are outside the axis limits
arthritis; RS3PE, remitting seronegative symmetrical synovitis with pitting edstiffness was defined as ≥30 or ≥90 minutes consistent re-
sults were observed (Table 3). The AUCs of the presence
of morning stiffness for RA in both cohorts were 0.68
(95% CI 0.66 to 0.70) and 0.64 (95% CI 0.58 to 0.69). The
duration with the optimal combination of sensitivity and
specificity for RA was 27.5 minutes in the EAC and
25.0 minutes in ESPOIR (Figure 3).
Both cohorts also recorded the severity of morning
stiffness. In both cohorts morning stiffness duration andC. The black horizontal line indicates the median duration. Number
E with peripheral arthritis n = 21, sarcoidosis n = 78, RS3PE n = 60,
heral arthritis n = 287, crystal arthritis n = 119. Two data points (2010-RA
. EAC, Early Arthritis Clinic; PsA, psoriatic arthritis; RA, rheumatoid
ema; SLE, systemic lupus erythematosus; SpA, spondyloarthritis.
Table 3 The diagnostic value of morning stiffness (duration and severity) in early arthritis for classifying RA
OR (95% CI) adjusted for
age and gender
OR (95% CI) adjusted for age,
gender, SJC, ACPA, RF ESR
and symptom duration
Sensitivity Specificity PPV NPV
Leiden EAC
≥30 minutes 3.37 (2.83-4.03) 2.22 (1.66-2.96) 77.0% 51.5% 53.5% 75.5%
≥60 minutes 2.92 (2.47-3.44) 1.72 (1.31-2.25) 61.2% 66.1% 56.7% 70.1%
≥90 minutes 2.44 (2.04-2.92) 1.61 (1.19-2.18) 39.1% 80.3% 59.0% 64.5%
VAS 34-67 mm 1.87 (1.48-2.36) 2.10 (1.43-3.09) 56.5% 60.0% 49.1% 66.8%
VAS ≥68 mm 2.38 (1.89-3.00) 1.93 (1.32-2.83) 60.7% 61.8% 55.3% 66.8%
ESPOIR
≥30 minutes 2.64 (1.81-3.87) 1.76 (1.07-2.88) 74.2% 47.8% 87.6% 27.1%
≥60 minutes 2.33 (1.59-3.44) 1.68 (1.03-2.74) 55.4% 64.7% 88.7% 22.6%
≥90 minutes 2.02 (1.28-3.20) 1.64 (0.92-2.92) 32.5% 80.9% 89.4% 19.4%
VAS 34-67 mm 2.04 (1.32-3.17) 1.93 (1.10-3.37) 61.0% 56.3% 85.7% 25.1%
VAS 68–100 mm 2.46 (1.53-3.96) 1.65 (0.88-3.11) 57.3% 63.7% 87.6% 25.1%
RA is classified according to the 2010 ACR-EULAR criteria. VAS: (0 to 100 mm). In the analyses of VAS morning stiffness three categories were formed, the reference
group was a VAS 0 to 33 mm. The sensitivity, specificity, PPV and NPV of the VAS morning stiffness were calculated against this reference group. RA, rheumatoid
arthritis; OR, odds ratio; CI, confidence interval; SJC, swollen joint count; ACPA, anti-citrullinated protein antibody; RF, rheumatoid factor; ESR, erythrocyte
sedimentation rate; PPV, positive predictive value; NPV, negative predictive value; EAC, Early Arthritis Clinic; VAS, visual analogue scale; ESPOIR, Evaluation et
Suivi de POlyarthrites Indifférenciées Récentes; ACR, American College of Rheumatology; EULAR, European League Against Rheumatism.
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EAC and Spearman rho 0.54, P <0.001 in ESPOIR) Early
arthritis patients with moderate severity (VAS 34 to
67 mm) had an OR on RA of 1.87 (95% CI 1.48 to 2.36)
and 2.04 (1.32 to 3.17) and the patients in the most severe
category (VAS ≥68 mm) had ORs of 2.38 (95% CI 1.89 to
3.00) and 2.46 (95% CI 1.53 to 3.96) respectively. Using
the VAS, the AUCs were 0.62 (95% CI 0.60 to 0.65) in
EAC and 0.62 (95% CI 0.57 to 0.68) in ESPOIR. The
AUCs of morning stiffness duration and morning stiffness
severity were not statistically significantly different.
Prognostic value of morning stiffness in early RA
RA patients reporting morning stiffness (≥60 minutes) at
baseline did not have more severe radiographic progres-
sion (Figure S1A, B in Additional file 1) over time. During
10 years of follow-up, 23% (n = 257) of the RA patients in
the EAC obtained DMARD-free sustained remission; in
ESPOIR this was 10% (n = 65) during five years of
follow-up. Morning stiffness (≥60 minutes) was not associ-
ated with achieving remission (Figure S1C, D in Additional
file 1). Defining morning stiffness as ≥30 or ≥90 minutes or
using VAS scores did not evidently change the results
(Figure S1E-H in Additional file 1). In 128 EAC RA pa-
tients that achieved remission (after median 2.4 years) the
VAS at inclusion and at time of remission were available; it
declined from 52.5 mm at baseline (IQR 25.8 to 75.8) to
13.5 mm (IQR 1.3 to 35.8, P <0.005).
Discussion
Morning stiffness is one of most commonly evaluated
symptoms in the diagnostic process of joint symptomsbecause its presence is thought to be characteristic for
arthritis or RA. Others, however, have doubted the value
of morning stiffness in this respect [4,5]. The absence of
large-scale studies on the diagnostic value of morning
stiffness prompted us to initiate the present study. The
subject is timely because of the current focus on early
identification of arthritis and RA [17,21]. Furthermore,
assessing the presence of or duration of morning stiff-
ness is relatively easy, illustrating its potential utility. We
aimed to determine the diagnostic and prognostic value of
morning stiffness. To this end we performed a comprehen-
sive study in different types of patients. We observed that
arthralgia patients with morning stiffness for ≥60 minutes
more often had arthritis than patients without morning
stiffness, but the discriminative ability of this single variable
(AUC) was low. Among early arthritis patients, RA patients
experienced morning stiffness more frequently. Also here
the discriminative ability of morning stiffness alone was
moderate. This indicates that evaluation of morning stiff-
ness is helpful in the diagnostic process in clinical practice
but that it should be combined with other characteristics
for optimal discrimination.
Advantageous in this study is that morning stiffness
was evaluated in many arthralgia and early arthritis pa-
tients (>5,000 in total) included in several European co-
horts. The arthralgia datasets had different inclusion
criteria. The studied EARC arthralgia patients were re-
ferred by their GPs because they doubted the presence of
arthritis. The threshold for referral to the EARCs was low
and the GP delays short. [13] Although the diagnostic
value of morning stiffness of persons with joint symptoms
in general practices was not studied, the arthralgia patients
Figure 3 ROC curves on morning stiffness in early arthritis patients
of the EAC (A) and ESPOIR (B). The AUCs were 0.68 in the EAC and
0.64 in ESPOIR. In the EAC, the optimal cutoff point (crossing of dashed
lines) reflected a sensitivity of 77% and a specificity of 52%; morning
stiffness duration at this point was 27.5 minutes. When selecting the
point with 80% specificity, the sensitivity was 40% and the morning
stiffness duration 67.5 minutes (EAC) and a sensitivity of 33% and a
morning stiffness duration 62.5 minutes (ESPOIR). AUC, area under
the receiver operating characteristic curve; EAC, Early Arthritis Clinic;
ESPOIR, Evaluation et Suivi de POlyarthrites Indifférenciées Récentes.
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which GPs were concerned about the presence of arthritis.
Patients in REACH had to fulfil several criteria. Presenceof morning stiffness was a criterion, explaining the higher
median duration of morning stiffness in REACH patients.
Despite the differences in patients’ selection, the test char-
acteristics of morning stiffness for arthritis in the different
arthralgia datasets were comparable, which strengthens
the validity of the findings.
The early arthritis cohorts also had different inclusion
criteria. ESPOIR included patients that were considered
susceptible to have or develop RA, whereas the EAC in-
cluded all types of early arthritis patients. Consequently,
the percentage of patients fulfilling the 2010 criteria at
year one and the PPV were higher in ESPOIR than in
the EAC and the difference in morning stiffness between
RA and non-RA patients was larger in the EAC. None-
theless, the ORs, AUCs and test characteristics were
almost similar between the cohorts, supporting the
consistency of the findings.
Emery et al. proposed that the suspicion of RA is in-
creased in the presence of ≥3 swollen joints, a positive
squeeze test or morning stiffness ≥30 minutes. Data sup-
porting the latter recommendation were not published
before [3] but the present data support this recommen-
dation as in early arthritis with RA as outcome, the best
sensitivity-specificity combination (sensitivity 74 to 77%,
specificity 48 to 52%) was present for morning stiffness
enduring ≥30 minutes. However, it should be noted that
the AUCs were not high and that it remains debatable
whether the discriminative ability of ≥30 minutes is clearly
superior to other durations. In addition, when one should
aim for a specificity of 80%, to reduce false positive results,
a cutoff of ≥60 minutes is required (EAC 67.5 minutes,
ESPOIR 62.5 minutes, Figure 3).
The outcome in early arthritis was fulfilling the 2010-
RA criteria after one year; generally diagnoses are definite
then [22]. We did not intend to evaluate the predictive
ability of morning stiffness for RA in undifferentiated arth-
ritis as done previously [22,23]. We aimed to determine
the discriminative ability of morning stiffness in early arth-
ritis for RA and to this end the diagnosis had to be ascer-
tained with as much certainty as possible.
Our findings that morning stiffness is associated with
2010-RA, independent of other characteristics (for ex-
ample ACPA, RF, SJC, ESR), are in contrast with the ab-
sence of morning stiffness in the 2010 criteria [22]. This
is noteworthy as the cohorts studied here were also in-
cluded in the first phase of the derivation of the criteria.
Several factors may play a role. First, in the derivation
process patients with diagnoses other than RA or unclassi-
fied arthritis (UA) were excluded, diminishing the contrast
between the groups (for comparison we observed a larger
difference within the EAC than within ESPOIR). Second,
the outcome was methotrexate initiation whereas we here
studied fulfilling the 2010 criteria. Furthermore, morning
stiffness was missing in 760 out of 3,115 patients included
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in the different cohorts (present/absent, </≥1 hour or
some categories on duration) [10]. This heterogeneity in
data collection contributed to the fact that morning
stiffness was voted out in phase 1 [10]. Nevertheless, the
present data reveal that patients with 2010-RA more
often suffer with morning stiffness than other early
arthritis patients. This association is independent of the
variables in the 2010 classification criteria for RA. In
our view, the present data suggest that it is helpful to
evaluate morning stiffness in addition to the other items
of the 2010 criteria. However, we did not intend to re-
fine the 2010 ACR/EULAR criteria for RA. For refine-
ment of existing criteria, a different approach, involving
many rheumatologists from Europe and the USA and
focusing on reaching consensus, would be required.
Our study in early arthritis assessed morning stiffness in
two ways: the questions related to the duration and the se-
verity (on a VAS). It has been reported that such descrip-
tions poorly define the experiences of patients, which
encompass temporal patterns, intensities and functional
disability in the early morning [24,25]. To our knowledge,
no validated method is available to evaluate these items.
Thus, exploration of such items may increase the diagnos-
tic ability of morning stiffness but were not explored here.
A limitation of our data on the severity of morning
stiffness is that VAS data were missing in 19% of EAC
RA patients at baseline and in almost 50% of the RA pa-
tients who achieved DMARD remission at the time of
remission. A previous study on 143 patients reported that
morning stiffness severity is more responsive than morn-
ing stiffness duration [26]. We did not study the respon-
siveness of morning stiffness but noted that morning
stiffness had almost disappeared when DMARD-free sus-
tained remission was achieved. Furthermore, we also did
not intend to study in detail whether the severity or the
duration of morning stiffness is a better discriminator.
Nonetheless, we did observe in early arthritis patients that
both measures correlated moderately and that the AUC of
morning stiffness severity was not superior to that of
morning stiffness duration.
Another limitation of this study is that no longitudinal
evaluations on the arthralgia patients were done. Recently,
a prediction rule for arthritis development in ACPA-
positive arthralgia patients was derived and morning stiff-
ness ≥1 hour was part of this rule [27]. This supports the
notion that including morning stiffness in the diagnostic
process is valuable. More longitudinal studies on arthral-
gia patients are needed.
Although the circadian rhythm is associated with nightly
activation of the inflammatory processes and elevation of
pro-inflammatory cytokines (for example TNF-α and
IL-6) [28-30], the exact mechanisms causing the stiff-
ness in the early morning are unknown. In addition. thecortisol rhythm might contribute to the increased in-
flammation at night due to the low nocturnal levels of
cortisol [31]. Despite the association with inflammation,
morning stiffness at first presentation of RA was not asso-
ciated with radiological progression or RA persistence over
time. Other studies reported that morning stiffness is asso-
ciated with functional disability, and work loss and there-
fore impacts on individual RA patients’ lives [2,11,12].
Conclusions
The additional relevance of present data is that it pro-
vides evidence, for the first time on a large study, that
incorporating morning stiffness in the diagnostic process
of joint symptoms in daily practice is valuable. A dur-
ation of morning stiffness of 30 minutes had the best
combination of sensitivity and specificity (74 to 77% and
48 to 52% respectively). However, in case one prefers to
be specific (specificity ≥80%) a cutoff duration of 60 mi-
nutes is preferable.
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